with TAMRA and/or FAM) for the amplified sequence. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample may be dot blotted without size separation. The fusion protein may further comprise a second amino acid sequence comprising an amino acid sequence selected from the group consisting of a second SARS virus protein, a non-SARS virus protein, a bacterial protein, and an adjuvant.Accordingly, the invention includes a polypeptide comprising a fragment of SEQ ID NO: 6049 wherein said fragment does not include one or more of the hydrophobic amino acid sequences identified above. The cells are evaluated to determine if a marker in the cells has been inhibited by the modified siRNA.4-N-substituted-2-N-substituted-5-fluorobenzenecarbonitrile was reduced with DIBAL-H according to procedure described in Scheme 10 to give 4-N-substituted-2-N-substituted-5-fluorobenzaldehyde.57. SEQ ID NO: 6040 is predicted to be located in one of the following locations: mitochondrial matrix space, microbody (peroxisome), nucleus, and mitochondrial inner membrane. A vaccine of one of claims 22 to 37, and 90 to 93 further comprising an adjuvant.34. The invention further includes a polypeptide comprising a fragment of SEQ ID NO: 6051 wherein said fragment does not include one or more of the amino acid residues of SEQ ID NO: 6051 selected from the group consisting of Ser-79; Thr-92; Ser-106; Thr-116; Thr-142; Ser-184; Ser-188; Ser-202; Ser-236; Thr-248; Ser-251; Ser-256; Thr-377.
As used herein, the term agent, substance or compound is intended to mean a protein, nucleic acid, carbohydrate, lipid, polymer or a small molecule, such as a drug.Other cell based assays are known in the art and include, among others, methods of GFP detection and Luc detection. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.Another preferred fragment of HR1 comprises amino acid residues 901 to 1005 of SEQ ID NO: 6042.
Preferably, the (i) first primer comprises a sequence which is substantially identical to a portion of a sequence selected from the group consisting of SEQ ID NO: 7292 and SEQ ID NO: 7293. Rhodes et al., 1991, AIDS 5:145-151; Sezakiel et al., 1992, J. Virol. PP20480.012, filed on Aug. 14, 2003 via Express Mail with the US post office, U.S. provisional patent application 60/505,652, Attorney Reference No. The invention includes an antibody which recognizes a polypeptide comprising SEQ ID NO: 7232 or a fragment thereof.In one embodiment, a lower concentration of SARS viral antigen is used in split vaccine compositions of the invention. 65:468-472; Chatterjee et al., 1992, Science 258:1485-1488; Rhodes et al., 1990, J. Gen. Virol. Column fractions containing SARS-CoV spike proteins were applied to MagneHis Protein purification system (Promega) following the protocol suggested by the manufacturer.Another example of a SARS virus isolate is set forth in Example 1 below. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess.